{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:33:12Z","timestamp":1791639192023,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The prognostic relevance of tumor-infiltrating lymphocytes (TILs) has so far been recognized in several solid tumors like in breast, endometrial and ovarian cancer\u2014nonetheless, the immune contexture of squamous cell carcinomas of the vulva, analyzed by means of stromal (s) and intratumoral (i) TILs, remains yet to be elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and methods<\/jats:title>\n            <jats:p>In this study, we examined the immunooncological biomarkers sTILs and iTILs in 157 vulvectomy specimens with histologically diagnosed vulvar squamous cell carcinoma (VSCC) according to the standardized methodology proposed by the <jats:italic>International Immunooncology Biomarkers Working Group<\/jats:italic> in 2017. In a next step, we evaluated the association of infiltrating lymphocytes to traditional histopathological parameters such as infiltration depth and HPV related tumorigenesis. After determining optimal cut-off values using Receiver Operating Characteristic (ROC) curve analysis, we assessed the prognostic relevance of sTILs and iTILs with regard to overall survival, local recurrence, and metastasis using the Log-rank (Mantel\u2013Cox) test and Fisher's exact test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We propose optimal cut-off values of 5% for iTILs and 20% for sTILs analysis, which identify patients with a distinct superior survival rate (sTILs: <jats:italic>p<\/jats:italic>\u2009=\u20090.0137; iTILs: <jats:italic>p<\/jats:italic>\u2009=\u20090.0226). Furthermore, a low number of iTILs was associated with a higher risk of local recurrence in our study collective (<jats:italic>p<\/jats:italic>\u2009=\u20090.0432).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The fast and cost-effective determination of the histological biomarkers iTILs and sTILs yields prognostic relevance in vulvar cancer. A potential integration within the routine diagnostic workflow could be globally feasible, even in resource-poor settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-02381-x","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T16:39:11Z","timestamp":1745080751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Histopathological biomarkers in squamous cell carcinoma of the vulva: the prognostic relevance of tumor-infiltrating lymphocytes (TILs)\u2014a retrospective study of 157 cases"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5358-2751","authenticated-orcid":false,"given":"Gilbert Georg","family":"Klamminger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios P.","family":"Nigdelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaman","family":"Degirmenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar Haj","family":"Hamoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich Franz","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schn\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Holleczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"2381_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"2381_CR2","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1158\/0008-5472.CAN-11-1316","volume":"71","author":"WH Fridman","year":"2011","unstructured":"Fridman WH, Galon J, Pag\u00e8s F, Tartour E, Saut\u00e8s-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011;71:5601\u20135.","journal-title":"Cancer Res"},{"key":"2381_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/annonc\/mdv560","volume":"27","author":"T Donnem","year":"2016","unstructured":"Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, et al. Strategies for clinical implementation of TNM-immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016;27:225\u201332.","journal-title":"Ann Oncol"},{"key":"2381_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the \u201cimmunoscore\u201d in the classification of malignant tumours. J Pathol. 2014;232:199\u2013209.","journal-title":"J Pathol"},{"key":"2381_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-016-0179-0","volume":"4","author":"KK Dobbin","year":"2016","unstructured":"Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume II\u2014clinical validation and regulatory considerations. J Immunother Cancer. 2016;4:77.","journal-title":"J Immunother Cancer"},{"key":"2381_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24:235\u201351.","journal-title":"Adv Anat Pathol"},{"key":"2381_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24:311\u201335.","journal-title":"Adv Anat Pathol"},{"key":"2381_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/modpathol.2011.211","volume":"25","author":"JN McAlpine","year":"2012","unstructured":"McAlpine JN, Porter H, K\u00f6bel M, Nelson BH, Prentice LM, Kalloger SE, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740\u201350.","journal-title":"Mod Pathol"},{"key":"2381_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2009","unstructured":"Clarke B, Tinker AV, Lee C-H, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393\u2013402.","journal-title":"Mod Pathol"},{"key":"2381_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"W-T Hwang","year":"2012","unstructured":"Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124:192\u20138.","journal-title":"Gynecol Oncol"},{"key":"2381_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203\u201313.","journal-title":"N Engl J Med"},{"key":"2381_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/modpathol.2014.143","volume":"28","author":"YR Hussein","year":"2015","unstructured":"Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28:505\u201314.","journal-title":"Mod Pathol"},{"key":"2381_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","volume":"1","author":"BE Howitt","year":"2015","unstructured":"Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319.","journal-title":"JAMA Oncol"},{"key":"2381_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.humpath.2007.05.022","volume":"39","author":"J Shia","year":"2008","unstructured":"Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39:116\u201325.","journal-title":"Hum Pathol"},{"key":"2381_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983\u201391.","journal-title":"J Clin Oncol"},{"key":"2381_CR16","volume-title":"Female genital tumours. WHO classification of tumours","author":"D Lokuhetty","year":"2020","unstructured":"Lokuhetty D, et al. Female genital tumours. WHO classification of tumours. 5th ed. Lyon: Internal Agency for Research on Cancer (IARC); 2020.","edition":"5"},{"key":"2381_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2381_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, M\u00fcller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105\u201313.","journal-title":"J Clin Oncol"},{"key":"2381_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"2381_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.anndiagpath.2018.05.007","volume":"35","author":"YA Kojima","year":"2018","unstructured":"Kojima YA, Wang X, Sun H, Compton F, Covinsky M, Zhang S. Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs working group 2014. Ann Diagn Pathol. 2018;35:77\u20139.","journal-title":"Ann Diagn Pathol"},{"key":"2381_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1471-0528.1988.tb06556.x","volume":"95","author":"JH Price","year":"1988","unstructured":"Price JH, Heath AB, Sunter JP, Sinha DP, Monaghan JM. Inflammatory cell infiltration and survival in squamous cell carcinoma of the vulva. BJOG. 1988;95:808\u201313.","journal-title":"BJOG"},{"key":"2381_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0090-8258(88)90267-3","volume":"31","author":"KC Rowley","year":"1988","unstructured":"Rowley KC, Gallion HH, Donaldson ES, van Nagell JR, Higgins RV, Powell DE, et al. Prognostic factors in early vulvar cancer. Gynecol Oncol. 1988;31:43\u20139.","journal-title":"Gynecol Oncol"},{"key":"2381_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0090-8258(89)90142-X","volume":"34","author":"N Husseinzadeh","year":"1989","unstructured":"Husseinzadeh N, Wesseler T, Schellhas H, Nahhas W. Significance of lymphoplasmocytic infiltration around tumor cell in the prediction of regional lymph node metastases in patients with invasive squamous cell carcinoma of the vulva: a clinicopathologic study. Gynecol Oncol. 1989;34:200\u20135.","journal-title":"Gynecol Oncol"},{"key":"2381_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/gyno.1993.1219","volume":"50","author":"B Bjerregaard","year":"1993","unstructured":"Bjerregaard B, Andreasson B, Visfeldt J, Bock JE. The significance of histology and morphometry in predicting lymph node metastases in patients with squamous cell carcinoma of the vulva. Gynecol Oncol. 1993;50:323\u20139.","journal-title":"Gynecol Oncol"},{"key":"2381_CR25","first-page":"28","volume":"38","author":"M Preti","year":"1993","unstructured":"Preti M, Micheletti L, Barbero M, Ghiringhello B, Valentino MC, Nicolaci P, et al. Histologic parameters of vulvar invasive carcinoma and lymph node metastases. J Reprod Med. 1993;38:28\u201332.","journal-title":"J Reprod Med"},{"key":"2381_CR26","first-page":"1113","volume":"35","author":"FS Abr\u00e3o","year":"1990","unstructured":"Abr\u00e3o FS, Baracat EC, Marques AF, Abr\u00e3o MS, Torloni H, Coelho FR, et al. Carcinoma of the vulva. Clinicopathologic factors involved in inguinal and pelvic lymph node metastasis. J Reprod Med. 1990;35:1113\u20136.","journal-title":"J Reprod Med"},{"key":"2381_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2011.12.416","volume":"125","author":"RA de Jong","year":"2012","unstructured":"de Jong RA, Toppen NL, ten Hoor KA, Boezen HM, Kema IP, Hollema H, et al. Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. Gynecol Oncol. 2012;125:186\u201393.","journal-title":"Gynecol Oncol"},{"key":"2381_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/IGC.0b013e3182131f36","volume":"21","author":"JJ Sznurkowski","year":"2011","unstructured":"Sznurkowski JJ, \u017bawrocki A, Emerich J, Biernat W. Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2011;21:717\u201321.","journal-title":"Int J Gynecol Cancer"},{"key":"2381_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijgo.2007.07.019","volume":"100","author":"MR Raspollini","year":"2008","unstructured":"Raspollini MR, Asirelli G, Taddei GL. Analysis of lymphocytic infiltrate does not help in prediction of vulvar squamous cell carcinoma arising in a background of lichen sclerosus. Int J Gynecol Obstet. 2008;100:190\u20131.","journal-title":"Int J Gynecol Obstet"},{"key":"2381_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2011.04.050","volume":"122","author":"JJ Sznurkowski","year":"2011","unstructured":"Sznurkowski JJ, \u017bawrocki A, Emerich J, Sznurkowska K, Biernat W. Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol. 2011;122:307\u201312.","journal-title":"Gynecol Oncol"},{"key":"2381_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s40425-019-0712-z","volume":"7","author":"KE Kortekaas","year":"2019","unstructured":"Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, et al. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. J Immunother Cancer. 2019;7:236.","journal-title":"J Immunother Cancer"},{"key":"2381_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003671","volume":"9","author":"KE Kortekaas","year":"2021","unstructured":"Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, et al. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1\/PD-L1 immunotherapy. J Immunother Cancer. 2021;9: e003671.","journal-title":"J Immunother Cancer"},{"key":"2381_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/003335491012500106","volume":"125","author":"RT Greenlee","year":"2010","unstructured":"Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995\u20132004. Public Health Rep. 2010;125:28\u201343.","journal-title":"Public Health Rep"},{"key":"2381_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.hoc.2012.09.002","volume":"26","author":"GD Eslick","year":"2012","unstructured":"Eslick GD. What is a rare cancer? Hematol Oncol Clin North Am. 2012;26:1137\u201341.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2381_CR35","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345.","journal-title":"Nat Med"},{"key":"2381_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1352975","author":"R Schwab","year":"2024","unstructured":"Schwab R, Schiestl LJ, Cascant Ortolano L, Klecker PH, Schmidt MW, Almstedt K, et al. Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1352975.","journal-title":"Front Oncol"},{"key":"2381_CR37","first-page":"43","volume":"74","author":"MC Mihm","year":"1996","unstructured":"Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43\u20137.","journal-title":"Lab Invest"},{"key":"2381_CR38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/modpathol.2017.43","volume":"30","author":"L Buisseret","year":"2017","unstructured":"Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, et al. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017;30:1204\u201312.","journal-title":"Mod Pathol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02381-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T16:39:12Z","timestamp":1745080752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02381-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02381-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the responsible Ethics Committee of Saarland. As no personal data or images allowing identification of patients are presented, written consent was not required\/waived in this retrospective study in accordance with national law and the individual positive ethics vote (Ethics Committee of Saarland from the State Chamber of Physicians of Saarland; study identification number 249\/23, approved on 07. March 2024). All data were handled in accordance with this vote.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests\u00a0related\u00a0to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"572"}}